Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.20 USD

3.20
110,749

-0.04 (-1.23%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.18 -0.02 (-0.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 246)

Industry: Internet - Commerce

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myriad Genetics' Latest Alliance to Boost GeneSight Reach

by Zacks Equity Research

Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base

    Zacks Equity Research

    DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results

    by Zacks Equity Research

    Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.

      Zacks Equity Research

      Here's Why Investors Should Buy Luminex (LMNX) Right Now

      by Zacks Equity Research

      Luminex (LMNX) continues to grow strong on innovation and product launches.

        Zacks Equity Research

        Haemonetics (HAE) Grows on Strong Plasma, Competition Rife

        by Zacks Equity Research

        Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.

          Zacks Equity Research

          Quest Diagnostics, Clinical Genomics Ally, Oncology Strong

          by Zacks Equity Research

          Quest Diagnostics' (DGX) plan to distribute Clinical Genomics' FDA-approved InSure ONE is in line with the company's objective to lead in the high-potential oncology diagnostic market.

            Zacks Equity Research

            Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025

            by Zacks Equity Research

            Weight Watchers' (WTW) plan to issue senior notes will aid the company in reducing cost of capital.

              Zacks Equity Research

              Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens

              by Zacks Equity Research

              Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.

                Zacks Equity Research

                Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

                by Zacks Equity Research

                Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.

                  Zacks Equity Research

                  BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

                  by Zacks Equity Research

                  A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.

                    Zacks Equity Research

                    Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

                    by Zacks Equity Research

                    Bruker's (BRKR) recent acquisition of Germany-based MERLIN buoys optimism for its growth within MALDI Biotyper business.

                      Zacks Equity Research

                      AmerisourceBergen (ABC) Rewards Investors With Dividend Hike

                      by Zacks Equity Research

                      AmerisourceBergen's (ABC) dividend hike adheres to the company's policy of rewarding stakeholders at regular intervals.

                        Zacks Equity Research

                        OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3

                        by Zacks Equity Research

                        OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                          Zacks Equity Research

                          Inogen Claims Top Position in Deloitte List on Solid Growth

                          by Zacks Equity Research

                          Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.

                            Zacks Equity Research

                            QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition

                            by Zacks Equity Research

                            QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.

                              Zacks Equity Research

                              TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y

                              by Zacks Equity Research

                              TransEnterix's (TRXC) reports unimpressive Q3 results, thanks to the constriction of deferred service revenues.

                                Zacks Equity Research

                                Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife

                                by Zacks Equity Research

                                Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.

                                  Zacks Equity Research

                                  Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down

                                  by Zacks Equity Research

                                  Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.

                                    Zacks Equity Research

                                    Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag

                                    by Zacks Equity Research

                                    Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.

                                      Zacks Equity Research

                                      Hill-Rom (HRC) Banks on Product Launches, Competition Rife

                                      by Zacks Equity Research

                                      Hill-Rom (HRC) focuses on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging.

                                        Zacks Equity Research

                                        Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates

                                        by Zacks Equity Research

                                        At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.

                                          Zacks Equity Research

                                          Globus Medical (GMED) Q3 Earnings In Line, View Reiterated

                                          by Zacks Equity Research

                                          Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.

                                            Zacks Equity Research

                                            Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes

                                            by Zacks Equity Research

                                            Baxter's (BAX) convenient kidney dialysis solutions, regenerative tissue products, 3-in-1 oXIRIS set for continuous renal replacement therapy are the latest additions to the extensive product portfolio.

                                              Zacks Equity Research

                                              SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates

                                              by Zacks Equity Research

                                              SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.

                                                Zacks Equity Research

                                                Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up

                                                by Zacks Equity Research

                                                Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.

                                                  Zacks Equity Research

                                                  VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure

                                                  by Zacks Equity Research

                                                  VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.